How close are we to a vaccine in 100 days?Can we beat the next pandemic in 100 days?
or, simply: Can we beat the next pandemic in 100 days?or, precisely: How close are we to a vaccine in 100 days?
COVID compressed vaccine development from years to months; the goal is a repeatable 100 days from a new pathogen to authorized shots.COVID took 326 days. The target for the next pandemic is 100 — a vaccine before the outbreak spirals.
We are here
Platforms advance, mission unproven — CEPI reports 75+ supported candidates and platforms, with Lassa, Nipah and MERS vaccines in Phase II, but no 100-day authorization. Next up — CEPI 3.0 begins (expected 2027).
01 · Where we stand
Four tests between here and the goal
Each threshold is a falsifiable claim with a named next test. We move the meter only when a result is public.
Rapid Platform-to-Clinic TranslationDesign and test quickly✓ Achieved · Mar 2020
100%
Proven byNIH and Moderna dosed the first Phase I participant on day 66, proving rapid clinical entry but not authorization.
Response-Ready Prototype LibraryPrepare before the outbreakIn progress
55%
Next testCEPI 3.0 must publish viral-family coverage and demonstrate that a stored prototype can accelerate a novel related-virus response.
Authorization Within 100 DaysApprove within 100 daysEarly
31%
Next testThe next qualifying outbreak must reach authorization by day 100 with prospectively defined safety, efficacy and manufacturing evidence.
Manufacturing and Equitable DeliveryMake doses everywhereEarly
35%
Next testBy 2031 CEPI partners must document access to 1–2 billion doses of usable capacity and test activation, allocation and cross-border release.
THRESHOLDS — Thresholds for 100-Day Vaccines.
Scale
Measured Goal region
NOTE — This is the candidate file's recommended headline metric, but the two observations are not an apples-to-apples technology curve. The 2009 H1N1 vaccines used established seasonal-influenza plants and strain-change regulatory supplements; COVID-19 required a new coronavirus product and large efficacy trials. Both points stop at first authorization or rollout and therefore exclude the additional time required for mass manufacturing, allocation and population coverage.
02 · How we got here
The record behind the verdict
Major events set large; context events set small but never hidden. Everything below the TODAY rule is a schedule, not a result.
Learning to Induce Immunity moved the field from jenner tests cowpox protection to pasteur prevents rabies. The results narrowed the next question without closing it.
1796
Jenner tests cowpox protectionExperiment
Edward Jenner inoculated eight-year-old James Phipps with cowpox and later showed protection against smallpox.
Vaccines Become Industrial moved the field from influenza virus isolated to flu vaccine licensed. The results narrowed the next question without closing it.
1933
Influenza virus isolated
Smith, Andrewes and Laidlaw isolated influenza virus, making strain-matched vaccine development scientifically possible.
Programmable Platforms Emerge moved the field from messenger rna defined to ebola vaccines arrive late. The results narrowed the next question without closing it.
1961
Messenger RNA defined
Jacob and Monod defined messenger RNA, the transient genetic instruction later used by programmable vaccines.
Preparedness Meets a Pandemic moved the field from cepi launches at davos to first ebola vaccine licensed. The results narrowed the next question without closing it.
2017
CEPI launches at Davos
CEPI launched with $460 million in initial funding to advance vaccines before epidemics rather than starting during them.
The Hundred-Day Mission moved the field from curevac misses efficacy bar to cepi 3.0 begins. The results narrowed the next question without closing it.
2021
CureVac misses efficacy bar
CureVac's first-generation mRNA candidate reported 48% efficacy in its Phase 2b/3 final analysis.
Events outside the declared eras moved the field from coronavirus genome released to distributed capacity target matures. The results narrowed the next question without closing it.
2020
Coronavirus genome releasedExperiment
The SARS-CoV-2 genome sequence was released on January 10, establishing Day Zero for the COVID-19 vaccine sprint.
The learning curves and comparisons that justify each threshold's percentage. Every series is measured, with the source event linked in the timeline above.
The countdown
From 326 days to 100
226 daysto close
NOTE — This is the candidate file's recommended headline metric, but the two observations are not an apples-to-apples technology curve. The 2009 H1N1 vaccines used established seasonal-influenza plants and strain-change regulatory supplements; COVID-19 required a new coronavirus product and large efficacy trials. Both points stop at first authorization or rollout and therefore exclude the additional time required for mass manufacturing, allocation and population coverage.
Global procurement eventually reached enormous scale, but the first African shipment came 74 days after initial rollout and the 2026 value is CEPI's rounded 'nearly 2 billion' total.NOTE — Global procurement eventually reached enormous scale, but the first African shipment came 74 days after initial rollout and the 2026 value is CEPI's rounded 'nearly 2 billion' total.Manufacturing and delivery scale increased dramatically, but the points cover different populations, time windows and products and should not be treated as a productivity curve.NOTE — Manufacturing and delivery scale increased dramatically, but the points cover different populations, time windows and products and should not be treated as a productivity curve.
COVID-19 first rollout326 days
Mission target100 days
COMPARISON — COVID-19's record vaccine rollout was still more than three times the 100-day objective.
High-income countries50 % of adults, approximately
Most low-income countries2 % of adults, less than
COMPARISON — By August 2021, adult full-vaccination coverage differed by more than 25-fold between income groups.
People vaccinated40 million, more than
Additional GBS risk1 case per 100,000 vaccinees
COMPARISON — The 1976 campaign vaccinated over 40 million people despite detecting an excess GBS risk near one per 100,000 recipients.
2009 H1N1 first deployment20 weeks
Typical large-scale flu production26 weeks, approximately
COMPARISON — The H1N1 platform produced first deployable vaccines in 20 weeks versus roughly 26 weeks for traditional seasonal scale-up.
04 · What it unlocks
If the remaining tests pass
Downstream capabilities, drawn dashed because they depend on results not yet in.